Tibolone reduces fracture risk in osteoporotic women but increases stroke risk .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
The Effects of Tibolone in Older Postmenopausal Women
N Engl J Med. 2008 Aug 14;359(7):697-7084538 post-menopausal women (age 60-85) with low bone mineral density were randomized to either receive a daily dose of Tibolone (1.25mg) or an identical placebo. The results indicated that the use of tibolone resulted in a reduced risk for developing vertebral and non-vertebral fractures, invasive breast cancer as well as colon cancer. However, it is important to note that tibolone did increase the risk for stroke, and therefore should not be used as treatment in elderly women with other risk factors for stroke.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics